136 related articles for article (PubMed ID: 36774886)
1. Targeting leukemic stem cell subpopulation in AML using phytochemicals: An in-silico and in-vitro approach.
Brahmbhatt J; Kumar SP; Bhadresha K; Patel M; Rawal R
Comput Biol Med; 2023 Mar; 155():106644. PubMed ID: 36774886
[TBL] [Abstract][Full Text] [Related]
2. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.
Zhou B; Jin X; Jin W; Huang X; Wu Y; Li H; Zhu W; Qin X; Ye H; Gao S
J Transl Med; 2020 Jun; 18(1):254. PubMed ID: 32580769
[TBL] [Abstract][Full Text] [Related]
3. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
[TBL] [Abstract][Full Text] [Related]
4. Cardiac glycoside ouabain efficiently targets leukemic stem cell apoptotic machinery independent of cell differentiation status.
Poohadsuan J; O'Doherty GA; Owattanapanich W; Kungwankiattichai S; Rojanasakul Y; Issaragrisil S; Luanpitpong S
Cell Commun Signal; 2023 Oct; 21(1):283. PubMed ID: 37828578
[TBL] [Abstract][Full Text] [Related]
5. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
[TBL] [Abstract][Full Text] [Related]
6. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
8. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
9. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
10. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
[TBL] [Abstract][Full Text] [Related]
11. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
[TBL] [Abstract][Full Text] [Related]
12. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
Lim INX; Nagree MS; Xie SZ
Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
[TBL] [Abstract][Full Text] [Related]
13. Alternative splicing of HOXB-AS3 underlie the promoting effect of nuclear m6A reader YTHDC1 on the self-renewal of leukemic stem cells in acute myeloid leukemia.
Wu C; Cui J; Huo Y; Shi L; Wang C
Int J Biol Macromol; 2023 May; 237():123990. PubMed ID: 36906205
[TBL] [Abstract][Full Text] [Related]
14. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
15. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.
Dietrich PA; Yang C; Leung HH; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY
Blood; 2014 Nov; 124(22):3284-94. PubMed ID: 25293777
[TBL] [Abstract][Full Text] [Related]
16. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
17. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
18. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
19. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
